This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Oct;5(10):e546.

doi: 10.1016/S2352-3018(18)30259-5. Epub 2018 Oct 8.

Antiretroviral switch studies do matter

Eric S Daar¹, Peter Ruane², Edwin DeJesus³, Hans-Jürgen Stellbrink⁴, Jean-Michel Molina⁵

Affiliations

Affiliations

¹ Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA. Electronic address: edaar@labiomed.org.
² Ruane Clinical Research Group, Los Angeles, CA, USA.
³ Orlando Immunology Center, Orlando, FL, USA.
⁴ Infectious Disease Medical Center, Hamburg, Germany.
⁵ Department of Infectious Diseases, Saint-Louis Hospital, University of Paris Diderot, Paris, France.

PMID: 30319119
DOI: 10.1016/S2352-3018(18)30259-5

Comment

Antiretroviral switch studies do matter

Eric S Daar et al. Lancet HIV. 2018 Oct.

. 2018 Oct;5(10):e546.

doi: 10.1016/S2352-3018(18)30259-5. Epub 2018 Oct 8.

Authors

Eric S Daar¹, Peter Ruane², Edwin DeJesus³, Hans-Jürgen Stellbrink⁴, Jean-Michel Molina⁵

Affiliations

¹ Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA. Electronic address: edaar@labiomed.org.
² Ruane Clinical Research Group, Los Angeles, CA, USA.
³ Orlando Immunology Center, Orlando, FL, USA.
⁴ Infectious Disease Medical Center, Hamburg, Germany.
⁵ Department of Infectious Diseases, Saint-Louis Hospital, University of Paris Diderot, Paris, France.

PMID: 30319119
DOI: 10.1016/S2352-3018(18)30259-5

No abstract available

PubMed Disclaimer

Comment on

What did we learn from the bictegravir switch studies?
Harris M. Harris M. Lancet HIV. 2018 Jul;5(7):e336-e337. doi: 10.1016/S2352-3018(18)30099-7. Epub 2018 Jun 18. Lancet HIV. 2018. PMID: 29925488 No abstract available.
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, López-Cortés L, Ruane P, Podzamczer D, Brinson C, Custodio J, Liu H, Andreatta K, Martin H, Cheng A, Quirk E. Molina JM, et al. Lancet HIV. 2018 Jul;5(7):e357-e365. doi: 10.1016/S2352-3018(18)30092-4. Epub 2018 Jun 18. Lancet HIV. 2018. PMID: 29925489 Clinical Trial.
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, Custodio J, Andreatta K, Graham H, Cheng A, Martin H, Quirk E. Daar ES, et al. Lancet HIV. 2018 Jul;5(7):e347-e356. doi: 10.1016/S2352-3018(18)30091-2. Epub 2018 Jun 18. Lancet HIV. 2018. PMID: 29925490 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information